Navigation Links
Codexis Board Elects Pedro I. Mizutani, Raizen EVP, as Director
Date:7/28/2011

REDWOOD CITY, Calif., July 28, 2011 /PRNewswire/ -- Codexis, Inc. (Nasdaq: CDXS) today announced that Pedro I. Mizutani, Executive Vice President, Upstream Business, Raizen Energia Participacoes S.A, has been elected to the Codexis Board of Directors. Mr. Mizutani serves as the Board representative of Raizen, Brazil's largest sugar and ethanol producer. Raizen holds approximately 16% of Codexis' outstanding shares of common stock and is the company's largest stockholder.

"We are delighted to have Pedro Mizutani join our Board," said Alan Shaw, Ph.D., President and Chief Executive Officer. "He brings a wealth of executive experience in industrial, financial and agricultural operations, as well as an in-depth knowledge of the Brazilian fuels and sugar markets. Mr. Mizutani is widely known and respected in the Brazilian business community, and his deep industry knowledge and strategic counsel will bring immediate value to Codexis."

Mr. Mizutani joined Raizen in June 2011 and has responsibility for all upstream business (production of sugar, ethanol, and bioenergy). From 2000-2010, he was Director at Cosan Group with responsibility for all upstream production, and in 2010 was appointed CEO of Cosan Sugar and Ethanol. Cosan is one of the largest groups in Brazil, with businesses in energy, food, logistics, infrastructure and agricultural property management.

He holds a degree in production engineering from the University of Sao Paulo, an MBA from the Getulio Vargas Foundation and a post-graduate degree in finance from the Methodist University of Piracicaba. He has also attended extension courses in business management at Ohio University and the Kellogg School of Management at Northwestern University. Mr. Mizutani is a member of the Board of Directors of Cosan Group, UNICA, the Brazilian sugar trade association, and Centro de Tecnologia Canavieria, a sugarcane research center in Brazil.

Codexis is a clean technology company. Codexis develops optimized biocatalysts that make industrial processes faster, cleaner and more efficient. Codexis' technology is commercialized with leading global pharmaceutical companies and in development for advanced biofuels with shell and carbon capture. Other potential markets for the company's biocatalyst-enabled solutions include chemicals and water treatment. For more information, see www.codexis.com.

Contacts:
Media: Lyn Christenson, lyn.christenson@codexis.com, 650.421.8144 or Saskia Sidenfaden, ssidenfaden@mww.com, 212.827.3771 Investors: Henk Adriaenssens, ir@codexis.com, 650.421.8331


'/>"/>
SOURCE Codexis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Codexis Reports Second Quarter 2011 Results
2. Codexis and Chemtex to Collaborate on Sustainable Detergent Alcohols for the Household Products Market
3. Codexis to Present at the Pacific Crest and Canaccord Genuity Conferences
4. Codexis to Present at 3 Investor Conferences in June
5. Codexis Achieves Development Milestones With Teva
6. Codexis to Present at Barclays Conference
7. Codexis to Announce First Quarter 2011 Financial Results on May 5, 2011
8. Codexis Names Jacques Beaudry-Losique VP Corporate Development & Strategy
9. Codexis Announces Carbon Capture Progress at ARPA-E Summit
10. Codexis Names David Anton CTO & SVP, Process Development & Manufacturing
11. Codexis to Present at the Jefferies and Pacific Crest Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)...  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ... new treatments for cancer and other unmet medical ... announced underwritten public offering of 23,625,084 shares of ... of $2.00 per share, before deducting underwriting discounts ... Sorrento.  The net proceeds to Sorrento from this ...
(Date:4/19/2017)...  New research provides evidence that an old drug may ... study released today that will be presented at the ... Boston , April 22 to 28, 2017. ... disease, the oral drug levodopa has long been considered the ... the disease progresses, the effects of the medication can partially ...
(Date:4/19/2017)... 19, 2017  SARES•REGIS Group leased the first ... at Conejo Spectrum Business Park in ... Biotherapeutics, Inc. , a biopharmaceutical company developing meaningful ... that have been underserved by scientific innovation, with ... cancer, autoimmune and infectious disease. Before ...
Breaking Medicine Technology:
(Date:4/24/2017)... CO (PRWEB) , ... April 24, 2017 , ... ... American Educational Research Association’s Outstanding Public Communication of Education Research Award. The award ... public, including education communities. It recognizes a scholar who has demonstrated the capacity ...
(Date:4/24/2017)... ... April 24, 2017 , ... Sean Fay is the ... Bag, Sonicare Toothbrush, Juiceman Juicer, and the George Foreman Grill (which sold more than ... marketer in the last 25 years. , Now, due to changes in the broadcast ...
(Date:4/24/2017)... ... April 24, 2017 , ... The ... public support to bring their novel lifesaving device for the everyday use of ... medical-grade sensors, specially designed to read a child’s vital signs, and detect unusual ...
(Date:4/24/2017)... ... April 24, 2017 , ... According to the ... now claim the lives of 62 Americans each day.(1) Yet since 2011, the ... distributors, pharmacies and prescribers by more than half.(2) Novus Medical Detox Center ...
(Date:4/24/2017)... ... 2017 , ... Pitavastatin, a relatively new statin, has relevance ... to have significant interactions with antiretroviral therapy (ART). Among people living with ... inflammation in the bloodstream. , While lowering cholesterol and dampening inflammation are beneficial ...
Breaking Medicine News(10 mins):